ArticleResearch and practice in thrombosis and haemostasis2024

Caplacizumab improves clinical outcomes and is well tolerated across clinically relevant subgroups of patients with immune-mediated thrombotic thrombocytopenic purpura.

Katerina Pavenski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.